TSHA

Taysha Gene Therapies, Inc.

A clinical-stage biotech developing gene therapies for rare nervous-system diseases. Founded in 2019 out of the University of Texas Southwestern Medical Center in Dallas, its lead program TSHA-102 is designed to treat the genetic root cause of Rett syndrome by delivering a single MECP2 gene directly into the spinal fluid. The company takes its name from the Caddo word "taysha," meaning "friend" or "ally" — the same word that gave Texas its name.

CUSIP: 877619106HealthcareUS1 holder

Ownership Activity Financials Filings

Insiders

Ranked by how much each holding moved in the last 3 years

Manning Paul B10% owner · 3 transactions

31.77M—

as of Jun 2025

Bought 2.18M

Nolan Sean P.Chief Executive Officer, Director · 5 transactions

4.44M+189.2%

Granted 3.09M · Sold 178.1K

Stalfort John A IIIDirector · 3 transactions

2.06M+6.6%

Granted 127.2K

Alam KamranCHIEF FINANCIAL OFFICER · 9 transactions

1.44M+458.9%

Granted 1.38M · Sold 159.0K

Nagendran SukumarPresident and Head of R&D, Director · 18 transactions

1.34M+3804.7%

Granted 2.25M · Sold 1.14M

Donenberg Phillip B.Director · 3 transactions

241.3K+111.5%

Granted 127.2K

Long Alison SDirector · 3 transactions

127.2K—

Granted 127.2K

Sepp-Lorenzino LauraDirector · 3 transactions

127.2K—

Granted 127.2K

Insider	Stake change	Holds now	Granted / vested	Bought	Sold
Manning Paul B10% owner · 3 transactions	—	31.77Mas of Jun 2025	—	2.18M	—
Nolan Sean P.Chief Executive Officer, Director · 5 transactions	+189.2%	4.44M	3.09M	—	178.1K
Stalfort John A IIIDirector · 3 transactions	+6.6%	2.06M	127.2K	—	—
Alam KamranCHIEF FINANCIAL OFFICER · 9 transactions	+458.9%	1.44M	1.38M	—	159.0K
Nagendran SukumarPresident and Head of R&D, Director · 18 transactions	+3804.7%	1.34M	2.25M	—	1.14M
Donenberg Phillip B.Director · 3 transactions	+111.5%	241.3K	127.2K	—	—
Long Alison SDirector · 3 transactions	—	127.2K	127.2K	—	—
Sepp-Lorenzino LauraDirector · 3 transactions	—	127.2K	127.2K	—	—

Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.